It came just hours after Novavax announced its coronavirus vaccine – of which the UK has ordered 60 million doses. It is 89 percent effective at stopping infection and 86 percent effective against the new Kent variant of the virus.
More than 43,000 people from eight countries and three regions took part in trials of the single-shot vaccine from Johnson & Johnson, which was developed by its pharmaceutical arm Janssen.
Deliveries of the Janssen jab could begin arriving in Britain in the second half of the year, provided it receives the green light from regulators.
Dr Paul Stoffels, Johnson & Johnson’s chief scientific officer, said the jab could significantly ease the burden on health services across the world, particularly as only one dose